🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Tianjin Medical University General Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Tianjin Medical University General Hospital as lead sponsor. Synced 26 Sep 2026
18Current trials
9Recruiting now
14Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Tianjin Medical University General Hospital is the lead sponsor of 18 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Esketamine, Atorvastatin and Baricitinib. The most-studied condition is NMO Spectrum Disorder.

ClinicalTrials.gov trials by status

  • Recruiting950%
  • Not yet open528%
  • Active, closed422%

Trials by phase

  • Not applicable528%
  • Phase 2422%
  • Phase 1/2211%
  • Phase 2/3211%
  • Phase 3211%
  • Phase 116%
  • Phase 416%
  • Observational16%
01

Clinical trials sponsored by Tianjin Medical University General Hospital

18 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients
NCT06108830 · ClinicalTrials.gov ↗ · Sleep Disturbance
Not applicable Recruiting 2023-12 China
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 · ClinicalTrials.gov ↗ · Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple
Phase 1/2 Recruiting 2024-11 China
Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes
NCT06746610 · ClinicalTrials.gov ↗ · Monogenic Diabetes
Not applicable Recruiting 2022-08 China
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
NCT07022197 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder, Myasthenia Gravis
Phase 1/2 Recruiting 2025-04 China
Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
NCT07018375 · ClinicalTrials.gov ↗ · Chronic Postsurgical Pain
Phase 4 Recruiting 2026-01 China
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
NCT06327451 · ClinicalTrials.gov ↗ · Glioblastoma, IDH-wildtype
Phase 2 Recruiting 2024-04 China
China Monogenic Diabetes Registry
NCT07492004 · ClinicalTrials.gov ↗ · Neonatal Diabetes, Monogenic Diabetes, Maturity Onset Diabetes of the Young
Observational Recruiting 2021-02 China
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
NCT07420296 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorders (NMOSD)
Phase 3 Recruiting 2026-01 China
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
NCT05369351 · ClinicalTrials.gov ↗ · Intracerebral Haemorrhage
Phase 2 Recruiting 2024-01 China
Normal Saline Infusion After Intravenous Thrombolysis in Stroke
NCT07497542 · ClinicalTrials.gov ↗ · Brain Infarction
Phase 3 Not yet open 2026-04 China
The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery
NCT07760740 · ClinicalTrials.gov ↗ · Cholestatic Pruritus
Not applicable Not yet open 2026-08 China
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
NCT07758062 · ClinicalTrials.gov ↗ · Glioblastoma
Phase 2 Not yet open 2026-09 China
The Effect of a Single Intravenous Injection of Esketamine During Cesarean Section on Postoperative Pruritus in Patients With Intrahepatic Cholestasis of Pregnancy
NCT07560722 · ClinicalTrials.gov ↗ · Intrahepatic Cholestasis of Pregnancy
Not applicable Not yet open 2026-05 China
The Effect of Intraoperative Esketamine Infusion on Pruritus in Elderly Surgical Patients
NCT07597486 · ClinicalTrials.gov ↗ · Senile Pruritus
Not applicable Not yet open 2026-05 China
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT07184840 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Attack
Phase 2 Active, closed 2025-09 China
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NCT05792462 · ClinicalTrials.gov ↗ · NMO Spectrum Disorder
Phase 1 Active, closed 2023-04 China
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
NCT05403138 · ClinicalTrials.gov ↗ · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
Phase 2/3 Active, closed 2022-11 China
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT06452537 · ClinicalTrials.gov ↗ · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Phase 2/3 Active, closed 2024-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Tianjin Medical University General Hospital trials

14 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Tianjin Medical University General Hospital trials

25 conditions
NMO Spectrum Disorder3Monogenic Diabetes2Neuromyelitis Optica Spectrum Disorder Attack1Sleep Disturbance1Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)1AML (Acute Myelogenous Leukemia)1Myeloma Multiple1B-ALL1Chronic Inflammatory Demyelinating Polyradiculoneuropathy1Myasthenia Gravis1Idiopathic Inflammatory Myopathies1Chronic Postsurgical Pain1Neuromyelitis Optica1Neuromyelitis Optica Spectrum Disorder1Glioblastoma, IDH-wildtype1Neonatal Diabetes1Maturity Onset Diabetes of the Young1Brain Infarction1Neuromyelitis Optica Spectrum Disorders (NMOSD)1Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease1Cholestatic Pruritus1Glioblastoma1Intrahepatic Cholestasis of Pregnancy1Intracerebral Haemorrhage1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China189

A trial with sites in more than one country appears in each of those registers.

05

Questions about Tianjin Medical University General Hospital trials

How many clinical trials does Tianjin Medical University General Hospital sponsor?

Tianjin Medical University General Hospital is the lead sponsor of 18 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tianjin Medical University General Hospital trials recruiting?

Yes. 9 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Tianjin Medical University General Hospital testing?

Its current trials name 14 drugs and biologicals as interventions. The most frequent are Esketamine (4), Atorvastatin (1), Baricitinib (1), Daratumumab (1) and Darzalex (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.